Background The use of antithrombotic agents, including anticoagulants, antiplatelet agents,
and thrombolytics has increased over the last decade and is expected to continue to rise …

Purpose Although therapeutic dosages of most low-molecular-weight heparins (LMWHs) are
known to accumulate in patients with renal insufficiency, for the lower prophylactic dosages …

INTRODUCTION: Rivaroxaban (RXA) is licensed for prophylaxis of venous
thromboembolism after major orthopaedic surgery of the lower limbs. Currently, no test to …

The ongoing National Institutes of Health–funded Bridge Trial will assess the safety and
efficacy of bridging therapy with low molecular weight heparin (LMWH) in the setting of atrial …

Background: Low-molecular-weight heparins (LMWH) have been shown to be safer, more
effective and more convenient than unfractionated heparin (UFH) in many clinical situations …

Clinical application of antithrombotic therapy in both arterial disease (acute coronary
syndromes, acute MI, peripheral arterial disease, valvular heart disease, atrial fibrillation) …

Background: Low‐molecular‐weight heparins (LMWH) are effective, safe and convenient for
anticoagulation. Their use is limited in patients with renal insufficiency (RI) because of …

The last 50 years have witnessed a multitude of publications evaluating the efficacy, safety
and cost effectiveness of many different thromboprophylaxis interventions. There is …

Elderly people with renal impairment are at high risk for venous thromboembolism (VTE)
and acute coronary syndromes (ACS); however, they are also at increased risk for bleeding …

BACKGROUND Low molecular weight heparins (LMWHs) have been cautiously used in
patients with chronic kidney disease (CKD) due to fear of accumulation. Dalteparin …